Zobrazeno 1 - 10
of 64
pro vyhledávání: '"S G Priori"'
Autor:
I. Graham, D. Ata, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backe, Sh. Ebrahim, B. Gjelsvik, Ch. Herrmann-Lingen, A. Hoes, S. Humphries, M. Knapton, J. Perk, S. G. Priori, K. Pyorala, Z. Reiner, L. Ruilope, S. Sans-Menendez, W. Scholte op Reime, P. Weissberg, D. Wood, J. Yarnell, J. L. Zamorano
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 4, Iss 4, Pp 90-107 (2016)
Externí odkaz:
https://doaj.org/article/19da95beea98413f8238a9904e982f2b
Autor:
I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, B. Gjelsvik, C. Herrmann-Lingen, A. Hoes, S. Humphries, M. Knapton, J. Perk, S. G. Priori, K. Pyorala, Z. Reiner, L. Ruilope, S. Sans-Menendez, W. Scholte op Reimer, P. Weissberg, D. Wood, J. Yarnell, J. L. Zamorano
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 4, Iss 3, Pp 111-128 (2016)
Externí odkaz:
https://doaj.org/article/2a552d900231463692bc9e47958d816c
Autor:
A Trancuccio, A Mazzanti, D Kukavica, G Giannini, M Memmi, P Gambelli, R Bloise, M Marino, M Morini, M Ortiz-Genga, C Napolitano, S G Priori
Publikováno v:
European Heart Journal. 43
Background Recently, a novel genetic-based classification for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) has been proposed to distinguish “typical” (RYR2 and CASQ2 genes) and “atypical” (TRDN, TECRL, CALM1–3, RYR2 loss-of-
Autor:
D Kukavica, A Mazzanti, A Trancuccio, G Giannini, M Marino, M Memmi, P Gambelli, R Bloise, M Morini, M Ortiz-Genga, C Napolitano, S G Priori
Publikováno v:
European Heart Journal. 43
Background Due to the catecholaminergic nature of arrhythmias that define the Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), beta-blockers (BBs) represent the first line therapy for this severe arrhythmogenic syndrome. Despite optimal
Autor:
A Mazzanti, A Trancuccio, D Kukavica, M Marino, G Giannini, L Rossetti, M Memmi, R Bloise, M Morini, C Napolitano, S G Priori
Publikováno v:
European Heart Journal. 43
Background Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a potentially fatal genetic arrhythmia syndrome and, despite optimal beta-blocker (BB) therapy, patients often experience life-threatening arrhythmic events (LAE). The role of
Autor:
S Marelli, A Trancuccio, Carlo Napolitano, M Morini, Andrea Mazzanti, S. G. Priori, D Kukavica, M Marino, Nicola Monteforte, Raffaella Bloise, T Chargeishvili
Publikováno v:
European Heart Journal. 41
Background Mexiletine has been proven effective in shortening the duration of ventricular repolarization and reducing the arrhythmic events in type 3 Long QT Syndrome (LQT3). Initial reports indicate that mexiletine might also be effective in patient
Autor:
M Marino, A Trancuccio, Carlo Napolitano, Nicola Monteforte, M Memmi, Raffaella Bloise, Andrea Mazzanti, L Braghieri, D Kukavica, M Morini, S. G. Priori
Publikováno v:
European Heart Journal. 41
Background Type 1 Long QT Syndrome (LQT1) is an arrhythmogenic disorder, caused by loss-of-function mutations on KCNQ1 gene, coding for Kv7.1 potassium channel. Although LQT1 is described as the most benign form of LQTS, patients still experience arr
Autor:
A Trancuccio, M Marino, S Marelli, Andrea Mazzanti, S. G. Priori, Carlo Napolitano, D Kukavica, T Chargeishvili, Nicola Monteforte, Raffaella Bloise
Publikováno v:
European Heart Journal. 41
Background Manual electrocardiographic (ECG) screening tools for the use of subcutaneous cardiac defibrillator (S-ICD) have been associated with high ineligibility rates in Brugada syndrome patients (BrS). Although recent works identified ECG paramet
Autor:
Esther Zorio, T Chargeishvili, A Trancuccio, Aristides Anastasakis, Eleonora Pagan, Sansone, Juan Jiménez-Jáimez, G Brugada, Luciana Sacilotto, S. G. Priori, Fernando E.S. Cruz, Eyal Nof, Andrea Mazzanti, Elżbieta Katarzyna Biernacka, D Guz
Publikováno v:
European Heart Journal. 41
Background Andersen-Tawil Syndrome type 1 (ATS1) in a rare arrhythmogenic disease caused by loss-of-function mutations in the KCNJ2 gene and characterized by ventricular arrhythmias, dysmorphic features and episodes of periodic paralysis. Although th
Autor:
Carlo Napolitano, R Bongianino, M Memmi, R Yanfei, Nicola Monteforte, Nian Liu, Raffaella Bloise, A Malovini, Andrea Mazzanti, M Morini, S. G. Priori, Valeria Novelli
Publikováno v:
European Heart Journal. 41
Background Inconsistent data support the role of CACNA1C as a disease-causing gene responsible for Brugada syndrome (BrS). As of today, the only gene consistently linked with BrS is SCN5A. Several CACNA1c genetic variants have been reported in associ